These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 1444304)

  • 1. Serum and blister fluid pharmacokinetics and bactericidal activities of ampicillin-sulbactam, cefotetan, cefoxitin, ceftizoxime, and ticarcillin-clavulanate.
    Jaresko GS; Barriere SL; Johnson BL
    Antimicrob Agents Chemother; 1992 Oct; 36(10):2233-8. PubMed ID: 1444304
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Survey of Bacteroides fragilis group susceptibility patterns in Canada.
    Bourgault AM; Lamothe F; Hoban DJ; Dalton MT; Kibsey PC; Harding G; Smith JA; Low DE; Gilbert H
    Antimicrob Agents Chemother; 1992 Feb; 36(2):343-7. PubMed ID: 1605600
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differences in the in vitro inhibitory and bactericidal activity of ceftizoxime, cefoxitin, cefotetan, and penicillin G against Bacteroides fragilis group isolates. Comparison of time-kill kinetic studies with MIC values.
    Aldridge KE; Weeks LS; Stratton CW; Sanders CV
    Diagn Microbiol Infect Dis; 1990; 13(4):311-6. PubMed ID: 2076592
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bactericidal activity of low-dose ceftizoxime plus metronidazole compared with cefoxitin and ampicillin-sulbactam.
    Freeman CD; Nightingale CH; Nicolau DP; Belliveau PP; Tessier PR; Fu Q; Xuan DW; Quintiliani R
    Pharmacotherapy; 1994; 14(2):185-90. PubMed ID: 8197037
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibitory and bactericidal activity of selected beta-lactam agents alone and in combination with beta-lactamase inhibitors compared with that of cefoxitin and metronidazole against cefoxitin-susceptible and cefoxitin-resistant isolates of the Bacteroides fragilis group.
    Stratton CW; Weeks LS; Aldridge KE
    Diagn Microbiol Infect Dis; 1992; 15(4):321-30. PubMed ID: 1611847
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of cefoxitin, cefotetan and the combination of ampicillin with sulbactam in the therapy of polymicrobial infection in mice.
    Brook I
    J Antimicrob Chemother; 1994 Nov; 34(5):791-6. PubMed ID: 7706175
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the post-antibiotic effect (PAE) induced by ceftizoxime, ceftriaxone, cefoxitin, ampicillin-sulbactam, and ticarcillin-clavulanate against selected isolates of Bacteroides fragilis and B. thetaiotaomicron.
    Aldridge KE
    Anaerobe; 2002 Dec; 8(6):295-9. PubMed ID: 16887672
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the inoculum effect of cefoxitin and other cephalosporins and of beta-lactamase inhibitors and their penicillin-derived components on the Bacteroides fragilis group.
    Goldstein EJ; Citron DM; Cherubin CE
    Antimicrob Agents Chemother; 1991 Sep; 35(9):1868-74. PubMed ID: 1952860
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activity of ampicillin/sulbactam, ticarcillin/clavulanate, clarithromycin, and eleven other antimicrobial agents against anaerobic bacteria isolated from infections in children.
    Citron DM; Goldstein EJ; Kenner MA; Burnham LB; Inderlied CB
    Clin Infect Dis; 1995 Jun; 20 Suppl 2():S356-60. PubMed ID: 7548597
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative in vitro beta-lactam activity against aerobic and anaerobic surgical isolates.
    Edmiston CE; Krepel CJ; Clausz JC; Condon RE
    Diagn Microbiol Infect Dis; 1988 Feb; 9(2):105-13. PubMed ID: 3164263
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multicenter study of in vitro susceptibility of the Bacteroides fragilis group, 1995 to 1996, with comparison of resistance trends from 1990 to 1996.
    Snydman DR; Jacobus NV; McDermott LA; Supran S; Cuchural GJ; Finegold S; Harrell L; Hecht DW; Iannini P; Jenkins S; Pierson C; Rihs J; Gorbach SL
    Antimicrob Agents Chemother; 1999 Oct; 43(10):2417-22. PubMed ID: 10508018
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the bactericidal activities of piperacillin-tazobactam, ticarcillin-clavulanate, and ampicillin-sulbactam against clinical isolates of Bacteroides fragilis, Enterococcus faecalis, Escherichia coli, and Pseudomonas aeruginosa.
    Klepser ME; Marangos MN; Zhu Z; Nicolau DP; Quintiliani R; Nightingale CH
    Antimicrob Agents Chemother; 1997 Feb; 41(2):435-9. PubMed ID: 9021203
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bactericidal activity of ceftizoxime, cefotetan, and clindamycin against cefoxitin-resistant strains of the Bacteroides fragilis group.
    Aldridge KE; Stratton CW
    J Antimicrob Chemother; 1991 Nov; 28(5):701-5. PubMed ID: 1778873
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Annual incidence, epidemiology, and comparative in vitro susceptibilities to cefoxitin, cefotetan, cefmetazole, and ceftizoxime of recent community-acquired isolates of the Bacteroides fragilis group.
    Goldstein EJ; Citron DM
    J Clin Microbiol; 1988 Nov; 26(11):2361-6. PubMed ID: 3235664
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro anaerobic data on ticarcillin/clavulanate. A review of an ongoing survey.
    Sanders CV; Aldridge KE
    J Reprod Med; 1990 Mar; 35(3 Suppl):313-6. PubMed ID: 2319513
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative study of pharmacokinetics and serum bactericidal activity of ceftizoxime and cefotaxime.
    Vallée F; LeBel M
    Antimicrob Agents Chemother; 1991 Oct; 35(10):2057-64. PubMed ID: 1759827
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro activities of antibacterial agents against clinical isolates of Escherichia coli and Klebsiella species from intensive care units.
    Gill CJ; Ponticas S; Shungu DL; Guerriero S
    Clin Ther; 1991; 13(1):25-37. PubMed ID: 2029725
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The antimicrobial susceptibility patterns of the Bacteroides fragilis group in the United States, 1987.
    Cornick NA; Cuchural GJ; Snydman DR; Jacobus NV; Iannini P; Hill G; Cleary T; O'Keefe JP; Pierson C; Finegold SM
    J Antimicrob Chemother; 1990 Jun; 25(6):1011-9. PubMed ID: 2370237
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of antibiotic activities by using serum bactericidal activity over time.
    Guglielmo BJ; Rodondi LC
    Antimicrob Agents Chemother; 1988 Oct; 32(10):1511-4. PubMed ID: 3056237
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Newer beta-lactam agents and the Bacteroides fragilis group.
    Cuchural GJ
    Pharmacotherapy; 1991; 11(2 ( Pt 2)):51S-55S. PubMed ID: 2041832
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.